{"gene":"CLN5","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1998,"finding":"CLN5 was identified by positional cloning as a novel gene encoding a putative transmembrane protein; three disease-causing mutations (one deletion, one nonsense, one missense) were identified in patients with Finnish variant late infantile neuronal ceroid lipofuscinosis.","method":"Positional cloning, sequence analysis of patient DNA samples","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — original positional cloning with multiple independent patient mutations confirmed in the same study, replicated across subsequent literature","pmids":["9662406"],"is_preprint":false},{"year":2002,"finding":"CLN5 protein is predominantly targeted to lysosomes and is a soluble lysosomal glycoprotein (~60 kDa glycosylated, ~38-40 kDa after deglycosylation), not an integral transmembrane protein as previously predicted. The most common Finnish vLINCL mutation blocked lysosomal targeting.","method":"Confocal immunofluorescence microscopy, immunoprecipitation, deglycosylation assays (Endo H, PNGase F) in transiently transfected BHK-21 cells","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal biochemical methods in a single study, replicated in subsequent work","pmids":["11971870"],"is_preprint":false},{"year":2002,"finding":"CLN5 directly interacts with CLN2 and CLN3 proteins based on co-immunoprecipitation and in vitro binding assays. Disease mutations in CLN5 abolished interaction with CLN2 but not CLN3. CLN5 is synthesized as four precursor forms from alternative initiator methionines; the longest membrane-associated form mediates interactions with CLN proteins.","method":"Co-immunoprecipitation, in vitro binding assays, Western blotting, mutagenesis","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — reciprocal Co-IP plus in vitro binding with disease-mutation validation in a single rigorous study","pmids":["12134079"],"is_preprint":false},{"year":2009,"finding":"CLN5 interacts with multiple NCL proteins: CLN1/PPT1, CLN2/TPP1, CLN3, CLN6, and CLN8. Over-expression of PPT1 can facilitate lysosomal transport of the mutated CLN5(FinMajor) protein normally retained in ER/Golgi. CLN5 also binds the F1-ATPase, a known PPT1-interacting partner.","method":"Co-immunoprecipitation, intracellular localization studies, co-expression assays","journal":"BMC cell biology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP supported by functional trafficking rescue, single lab but multiple interacting partners confirmed","pmids":["19941651"],"is_preprint":false},{"year":2012,"finding":"CLN5 interacts with the lysosomal sorting receptor sortilin. CLN5 depletion causes degradation of sortilin and the cation-independent mannose 6-phosphate receptor (CI-MPR) in lysosomes due to defective retromer recruitment at endosomes. CLN5 depletion also reduces active (GTP-loaded) Rab7, which is required for retromer recruitment.","method":"Co-immunoprecipitation, siRNA-mediated depletion in HeLa cells, Western blotting, fluorescence microscopy","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (Co-IP, KD with defined biochemical and trafficking phenotypes) in a single focused study","pmids":["22431521"],"is_preprint":false},{"year":2013,"finding":"CLN5 has eight functional N-glycosylation sites; glycosylation at specific asparagines (N179, N252, N304, N320) is required for proper protein folding (mutants retained in ER), while glycosylation at N401 is required for lysosomal trafficking (mutant mislocalizes to Golgi). Patient mutant N192S reaches the lysosome, suggesting a functional defect at that location.","method":"Site-directed mutagenesis of N-glycosylation sites, localization studies by fluorescence microscopy in transfected cells","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic site-directed mutagenesis of all eight N-glycosylation sites with localization readout, single lab","pmids":["24058541"],"is_preprint":false},{"year":2013,"finding":"CLN5 is synthesized as a type II transmembrane glycoprotein with a cytoplasmic N-terminus, one transmembrane segment, and a large luminal C-terminal domain containing an amphipathic helix (AH). The cytoplasmic and TM domains are removed by signal-peptide cleavage, and the mature CLN5 is anchored to the membrane lumen via the AH. CLN5 pathological mutants lacking the AH are retained in the ER and degraded by the proteasome.","method":"Epitope-tagged CLN5 topology mapping, membrane solubility assays, localization by fluorescence microscopy, proteasome inhibitor experiments","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic topology determination with epitope tagging plus mutagenesis of amphipathic helix and proteasomal degradation readout in a single study","pmids":["24038957"],"is_preprint":false},{"year":2015,"finding":"CLN5 undergoes proteolytic cleavage at its C-terminus in an acidic compartment, requiring a cysteine protease. A ~60 kDa proprotein form is processed to a ~56 kDa mature form post-translationally. Processing can occur as early as the trans-Golgi network.","method":"Cycloheximide chase analysis, pharmacological protease inhibitors, transient transfection of patient and glycosylation mutants, Western blotting","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (chase, inhibitors, mutants), single lab","pmids":["26342652"],"is_preprint":false},{"year":2017,"finding":"CLN5 is cleaved by SPPL3 (a member of the SPP/SPPL intramembrane protease family) from a type II transmembrane precursor into a mature soluble protein consisting of residues 93–407. The remaining N-terminal fragment is subsequently cleaved by SPPL3 and SPPL2b and degraded by the proteasome.","method":"Expression of tagged CLN5 constructs, overexpression/knockdown of SPPL family members, Western blotting, co-expression assays","journal":"Experimental cell research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct identification of the specific protease (SPPL3) with functional rescue and fragment characterization, single lab but multiple orthogonal approaches","pmids":["28442266"],"is_preprint":false},{"year":2017,"finding":"Both Dictyostelium Cln5 and human CLN5 function as glycoside hydrolases, as shown using fluorescent enzyme substrates. Dictyostelium Cln5 is secreted during growth and starvation and interacts with proteins involved in metabolism, catabolism, proteolysis, and hydrolysis including other NCL-like proteins (Tpp1/Cln2, cathepsin D/Cln10).","method":"Glycoside hydrolase fluorescent substrate assays, immunoprecipitation coupled with mass spectrometry, secretion assays, GFP fusion localization","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — enzyme activity demonstrated in vitro with fluorescent substrates for both Dictyostelium and human CLN5, single lab","pmids":["29128403"],"is_preprint":false},{"year":2018,"finding":"An AD-associated CLN5 variant (p.Asn320Ser) causes glycosylation defects, ER retention, and reduced delivery to the endolysosomal compartment. This variant reduces normal processing of cathepsin D and decreases levels of full-length amyloid precursor protein (APP), consistent with a defect in retromer-dependent trafficking.","method":"Expression of variant CLN5 in cells, Western blotting for glycosylation, immunofluorescence for localization, cathepsin D maturation assay, APP level measurement","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal assays (glycosylation, localization, downstream substrate processing) in a single focused study","pmids":["30037983"],"is_preprint":false},{"year":2021,"finding":"CLN5 and CLN3 function as an endolysosomal complex. CLN5 deletion results in impaired endolysosome fusion events, delayed degradation of endocytic proteins, and defective autophagy. CLN5 modulates these pathways by regulating downstream interactions between CLN3, RAB7A, and a subset of RAB7A effectors.","method":"CLN5 knockout/knockdown in HeLa cells, Co-immunoprecipitation for CLN3-RAB7A-effector interactions, endolysosome fusion assays, autophagy flux assays","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cellular assays plus Co-IP identifying the CLN3–RAB7A–effector regulatory axis, single lab","pmids":["34060589"],"is_preprint":false},{"year":2022,"finding":"CLN5 (Cln5) has cysteine palmitoyl thioesterase (S-depalmitoylation) activity. The crystal structure revealed homology to the catalytic domain of the N1pC/P60 superfamily of papain-like enzymes, and mutational analysis showed that the predicted catalytic residues histidine-166 and cysteine-280 are critical for thioesterase activity. CLN5-deficient neuronal progenitor cells show reduced thioesterase activity.","method":"Crystal structure determination, site-directed mutagenesis (H166A, C280A), fluorescent substrate (DDP-5) thioesterase assay, CLN5-deficient cell line thioesterase activity measurement","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus mutagenesis of catalytic residues plus in vitro enzyme activity plus loss-of-function cellular validation; multiple orthogonal methods in one study","pmids":["35427157"],"is_preprint":false},{"year":2022,"finding":"The CRL3-KCTD7 ubiquitin ligase complex targets CLN5 for ubiquitination and proteasomal degradation. NCL patient-derived KCTD7 mutations disrupt KCTD7–CUL3 or KCTD7–CLN5 interactions, causing excessive CLN5 accumulation. Accumulated CLN5 disrupts the interaction between CLN6/CLN8 and lysosomal enzymes at the ER, impairing ER-to-Golgi trafficking of lysosomal enzymes.","method":"Co-immunoprecipitation, ubiquitination assays, KCTD7 knockout/patient-mutation cell lines, Western blotting for lysosomal enzyme trafficking","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical reconstitution of ubiquitination, reciprocal Co-IP, disease-mutation functional rescue, and downstream pathway phenotype all in one study","pmids":["35921411"],"is_preprint":false},{"year":2023,"finding":"CLN5 is the lysosomal BMP synthase (BMPS). CLN5-deficient cells exhibit massive accumulation of the BMP precursor lysophosphatidylglycerol (LPG), depletion of BMP species, and dysfunctional lipid metabolism. Mechanistically, CLN5 mediates BMP synthesis through an energy-independent base exchange reaction between two LPG molecules, with increased activity on BMP-laden vesicles.","method":"BMPS-deficient cell generation, lipidomic profiling (LPG and BMP quantitation), in vitro enzymatic assay reconstitution with LPG substrates, BMP-laden vesicle activity assay","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted enzymatic activity in vitro with substrate identification and mechanistic (base exchange) characterization, plus orthogonal cellular lipidomics validation","pmids":["37708259"],"is_preprint":false},{"year":2023,"finding":"QM/MM computational analysis of the CLN5 crystal structure confirmed that S-depalmitoylation proceeds via a catalytic triad Cys280–His166–Glu183, and that S-depalmitoylation (barrier ~26.1 kcal/mol) is the rate-limiting step compared to the preceding S-palmitoylation step (~25.3 kcal/mol).","method":"QM/MM calculations at ωB97X-D/6-31G(d,p):AMBER level, NBO charge analysis, local mode stretching force constants","journal":"Journal of the American Chemical Society","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — rigorous computational mechanistic study grounded in the experimental crystal structure, but purely computational (no new experimental validation in this paper)","pmids":["38055807"],"is_preprint":false},{"year":2010,"finding":"CLN5 undergoes proteolytic cleavage to generate a mature polypeptide transported to lysosomes. CLN5 can also traffic to lysosomes via a mannose-6-phosphate receptor-independent pathway. All analyzed disease-causing mutations disrupt lysosomal trafficking of CLN5 proteins, but the degree of lysosomal mistargeting does not correlate with disease onset.","method":"Transient and stable expression in HeLa cells, pulse-chase metabolic labeling, immunofluorescence localization, M6P receptor blocking experiments","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple expression systems and biochemical methods demonstrating M6P-independent trafficking, single lab","pmids":["20052765"],"is_preprint":false},{"year":2009,"finding":"In cells lacking CLN5, lysosomal movement/trafficking is impaired in human cortical-like glutamatergic neurons, and lysosomal enzyme activity and acidic organelle content are reduced.","method":"CRISPRi knockdown of CLN5 in iPSC-derived human neurons, live-cell imaging of lysosomal movement, microscopy and flow cytometry for acidic organelles, lysosomal enzyme activity assay","journal":"Biomolecules","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPRi in human neurons with direct lysosomal movement imaging and functional enzyme assays, single lab","pmids":["34680045"],"is_preprint":false},{"year":2020,"finding":"CLN5 loss leads to mitochondrial dysfunction and impaired mitophagy. A mitochondria-focused proteomics approach in CLN5 KO cells and Cln5-/- mouse cerebral cortex revealed impairment of mitochondrial respiratory function and activation of mitophagy pathways, correlated with disease progression.","method":"Quantitative mitochondria-focused proteomics (label-free), mitochondrial respiration assays, immunofluorescence for mitophagy markers, validation in patient fibroblasts","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — orthogonal proteomics plus functional respiration assays in multiple disease models including patient cells, single lab","pmids":["32257390"],"is_preprint":false},{"year":2019,"finding":"CLN5 deficiency causes elevated basal LC3-II levels and increased autophagic flux in patient fibroblasts and CLN5-knockdown HeLa cells. Alpha-synuclein (α-syn) gene SNCA is highly upregulated at mRNA and protein levels in CLN5-deficient cells, and α-syn localizes near lysosomes. Knockdown of SNCA reversed lysosomal perinuclear clustering caused by CLN5 deficiency.","method":"Western blotting (LC3-II), tandem fluorescent mRFP-GFP-LC3 autophagy flux assay, qPCR for SNCA, immunofluorescence for α-syn localization, SNCA siRNA rescue experiment","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods with genetic rescue experiment (siRNA), single lab","pmids":["30655561"],"is_preprint":false},{"year":2024,"finding":"In Dictyostelium, Cln5 is released from cells via signal-peptide-mediated secretion and through pathways linked to autophagy. Release requires autophagy proteins Atg1, Atg5, and Atg9, as well as autophagosomal-lysosomal fusion. Release also requires microfilaments and Dictyostelium homologs of AP-3, LYST, mucopilin-1, and WASH (regulators of lysosomal exocytosis). Cln5 release is regulated by the amount of extracellular CtsD (cathepsin D).","method":"Genetic knockouts of autophagy genes, cytoskeleton inhibitor experiments, secretion assays with Western blotting and mass spectrometry in Dictyostelium","journal":"Traffic (Copenhagen, Denmark)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic genetic dissection with multiple knockout lines, single lab/model organism","pmids":["38272448"],"is_preprint":false},{"year":2009,"finding":"In wild-type CLN5 mutant cells (CLN5 p.Trp379Cys and p.Leu358AlafsX4), both mutant CLN5 proteins are retained in the endoplasmic reticulum rather than reaching the lysosome, as demonstrated by double immunofluorescence microscopy. The truncation mutant lacks an N-glycosylation site at Asn401.","method":"Double immunofluorescence microscopy, expression analysis, Western blotting in patient-derived cell lines","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization in patient-derived mutant cells, confirms Asn401 glycosylation requirement for lysosomal targeting, single study","pmids":["19309691"],"is_preprint":false},{"year":2004,"finding":"Mouse Cln5 is a soluble lysosomal glycoprotein. In situ hybridization and immunohistochemistry showed prominent expression in cerebellar Purkinje cells, cerebral neurons, hippocampal pyramidal cells, and interneurons, with expression beginning at E15 and increasing through development.","method":"In situ hybridization, immunohistochemistry, in vitro expression in COS-1, HeLa, and neuronal cells","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization and expression studies confirming soluble lysosomal nature in multiple cell types, single lab","pmids":["15207259"],"is_preprint":false},{"year":2012,"finding":"CLN5-deficient fibroblasts show decreased levels of ceramide, sphingomyelin, and glycosphingolipids, and reduced ceramide synthase activity. CLN8 protein expression can correct growth and apoptosis defects in CLN5-deficient cells. Comparison by Co-IP and differential gel electrophoresis revealed absence of γ-actin in the CerS1-bound protein complex in CLN5-deficient cells.","method":"Co-immunoprecipitation, differential gel electrophoresis, mass spectrometry, ceramide species measurement by MS, cell viability and apoptosis assays","journal":"Electrophoresis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical and proteomic methods in patient-derived cells, single lab","pmids":["23160995"],"is_preprint":false}],"current_model":"CLN5 encodes a soluble lysosomal glycoprotein that is translated as a type II transmembrane precursor, processed by SPPL3 intramembrane protease cleavage into a mature soluble form anchored by an amphipathic helix; it has at least two enzymatic activities—a BMP (bis(monoacylglycero)phosphate) synthase activity that catalyzes BMP biosynthesis via base exchange between two lysophosphatidylglycerol molecules, and a cysteine palmitoyl thioesterase (S-depalmitoylation) activity requiring catalytic residues His166 and Cys280; it regulates retromer recruitment to endosomes (in part by maintaining active Rab7 levels) to control lysosomal sorting receptor recycling, functions as part of an endolysosomal complex with CLN3 to regulate RAB7A effector interactions and endolysosome fusion, interacts with multiple other NCL proteins (CLN1/PPT1, CLN2/TPP1, CLN3, CLN6, CLN8), and is itself subject to ubiquitin-mediated degradation by the CRL3-KCTD7 E3 ligase complex."},"narrative":{"mechanistic_narrative":"CLN5 encodes a soluble lysosomal glycoprotein whose loss causes Finnish variant late infantile neuronal ceroid lipofuscinosis, a phenotype traced to multiple disease-causing mutations identified at its original positional cloning [PMID:9662406]. Although originally predicted to be a transmembrane protein, CLN5 is synthesized as a type II transmembrane precursor that is converted to a mature soluble lysosomal glycoprotein anchored to the luminal membrane leaflet by an amphipathic helix, with the cytoplasmic and transmembrane segments removed by SPPL3-mediated intramembrane proteolysis to yield mature residues 93–407 [PMID:11971870, PMID:24038957, PMID:28442266]. N-glycosylation governs both folding and trafficking, with distinct glycosylation sites required for ER exit versus lysosomal delivery, and CLN5 can reach lysosomes by a mannose-6-phosphate-receptor-independent route [PMID:24058541, PMID:20052765]; pathogenic mutants are mistargeted and retained in the ER for proteasomal degradation [PMID:24038957, PMID:19309691]. CLN5 carries two enzymatic activities: it is the lysosomal BMP synthase that builds bis(monoacylglycero)phosphate by an energy-independent base-exchange reaction between two lysophosphatidylglycerol molecules [PMID:37708259], and it is a cysteine palmitoyl thioesterase whose papain-like N1pC/P60 fold uses a Cys280–His166–Glu183 catalytic triad to mediate S-depalmitoylation [PMID:35427157, PMID:38055807]. Functionally, CLN5 controls endolysosomal sorting and fusion: it binds the sorting receptors sortilin and CI-MPR and sustains active Rab7 to support retromer recruitment at endosomes [PMID:22431521], and it acts with CLN3 to regulate RAB7A-effector interactions and endolysosome fusion, autophagy, and degradative flux [PMID:34060589]. CLN5 physically interacts with the broader NCL protein network (CLN1/PPT1, CLN2/TPP1, CLN3, CLN6, CLN8) [PMID:12134079, PMID:19941651], and its abundance is set by CRL3-KCTD7-mediated ubiquitination and proteasomal degradation, with KCTD7 disease mutations causing pathological CLN5 accumulation that disrupts CLN6/CLN8-dependent lysosomal enzyme trafficking [PMID:35921411]. Consistent with these roles, CLN5 deficiency produces lipid imbalance, impaired lysosomal motility and acidification in neurons, mitochondrial dysfunction, and dysregulated autophagy [PMID:37708259, PMID:34680045, PMID:32257390, PMID:30655561].","teleology":[{"year":1998,"claim":"Established CLN5 as a disease gene by linking its mutation to a defined neurodegenerative lysosomal storage disorder, providing the entry point for all mechanistic work.","evidence":"Positional cloning and patient DNA sequencing in Finnish variant late infantile neuronal ceroid lipofuscinosis","pmids":["9662406"],"confidence":"High","gaps":["The original cloning predicted a transmembrane topology that was later overturned","No molecular function assigned at identification"]},{"year":2002,"claim":"Resolved the basic nature and protein interactions of CLN5, showing it is a soluble lysosomal glycoprotein rather than an integral membrane protein and that it engages other NCL proteins.","evidence":"Confocal microscopy, deglycosylation, immunoprecipitation in BHK-21 cells, and reciprocal Co-IP/in vitro binding with disease-mutation validation","pmids":["11971870","12134079"],"confidence":"High","gaps":["Did not define the protease producing the soluble form","Functional consequence of CLN2/CLN3 binding unresolved"]},{"year":2009,"claim":"Expanded the NCL interaction network and showed cross-rescue of trafficking, establishing CLN5 as a hub among ceroid lipofuscinosis proteins.","evidence":"Co-IP, localization, and co-expression rescue assays plus patient-mutant ER retention in patient-derived cells","pmids":["19941651","19309691"],"confidence":"Medium","gaps":["Interactions largely single-lab Co-IP without reconstitution","Stoichiometry and directness of multi-NCL binding unclear"]},{"year":2012,"claim":"Defined a trafficking-regulatory function: CLN5 supports retromer-dependent recycling of lysosomal sorting receptors by maintaining active Rab7.","evidence":"Co-IP with sortilin, siRNA depletion in HeLa cells with receptor degradation and Rab7-GTP readouts","pmids":["22431521"],"confidence":"High","gaps":["Mechanism by which CLN5 sustains Rab7-GTP not defined","Whether enzymatic activity underlies the trafficking effect not addressed"]},{"year":2013,"claim":"Reconciled topology with maturation by showing CLN5 is a type II transmembrane precursor anchored after cleavage by an amphipathic helix, with N-glycosylation partitioned between folding and trafficking roles.","evidence":"Topology mapping with epitope tags, membrane solubility assays, systematic N-glycosylation site mutagenesis, proteasome inhibition","pmids":["24038957","24058541"],"confidence":"High","gaps":["Identity of the cleaving protease still unknown at this stage","Functional output of mature CLN5 not yet defined"]},{"year":2017,"claim":"Identified SPPL3 as the intramembrane protease generating mature soluble CLN5, closing the maturation pathway.","evidence":"Tagged CLN5 constructs with SPPL family overexpression/knockdown and fragment characterization by Western blot","pmids":["28442266","29128403"],"confidence":"High","gaps":["Glycoside hydrolase activity reported but substrate identity unresolved","Relationship between SPPL3 processing and downstream function unaddressed"]},{"year":2021,"claim":"Placed CLN5 in an endolysosomal complex with CLN3 that regulates RAB7A-effector interactions, linking it directly to endolysosome fusion and autophagy.","evidence":"CLN5 knockout/knockdown in HeLa cells, Co-IP of CLN3-RAB7A-effector axis, fusion and autophagy flux assays","pmids":["34060589"],"confidence":"Medium","gaps":["Direct biochemical architecture of the CLN5-CLN3 complex not solved","Single-lab functional dataset"]},{"year":2022,"claim":"Assigned a defined catalytic activity—cysteine palmitoyl thioesterase—via crystal structure and catalytic-residue mutagenesis, and showed CLN5 abundance is controlled by CRL3-KCTD7 ubiquitination.","evidence":"Crystal structure, H166A/C280A mutagenesis, fluorescent thioesterase assay, and ubiquitination assays with KCTD7 patient-mutation cell lines","pmids":["35427157","35921411"],"confidence":"High","gaps":["Physiological palmitoylated substrates of CLN5 thioesterase activity not identified","How thioesterase activity relates to trafficking phenotypes unresolved"]},{"year":2023,"claim":"Established CLN5 as the lysosomal BMP synthase and detailed the chemical mechanism of its second activity, giving the protein two distinct enzymatic functions.","evidence":"BMPS-deficient cells with lipidomics, in vitro reconstitution of LPG base-exchange, and QM/MM mechanistic analysis of S-depalmitoylation","pmids":["37708259","38055807"],"confidence":"High","gaps":["Whether BMP synthase and thioesterase activities use the same active site is not established","Which activity drives the disease phenotype unresolved"]},{"year":2023,"claim":"Characterized the cellular consequences of CLN5 loss across organelles, connecting the gene to lipid imbalance, neuronal lysosomal dysfunction, mitochondrial defects, and altered autophagy.","evidence":"iPSC-neuron CRISPRi imaging, mitochondrial proteomics in KO cells and Cln5-/- mouse cortex, autophagy flux and SNCA rescue, and Dictyostelium secretion genetics","pmids":["34680045","32257390","30655561","38272448","23160995"],"confidence":"Medium","gaps":["Causal ordering between primary enzymatic loss and downstream organelle phenotypes unclear","Many phenotypes are single-lab or model-organism observations"]},{"year":null,"claim":"It remains unresolved how CLN5's two enzymatic activities (BMP synthase and depalmitoylase) and its trafficking-regulatory role are mechanistically integrated, and which is the primary driver of neurodegeneration.","evidence":"No timeline study unifies the enzymatic and trafficking functions into a single causal model","pmids":[],"confidence":"Medium","gaps":["No defined physiological thioesterase substrate","No structural model linking active site to BMP synthesis","Disease-relevant primary defect unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[14]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[12,15]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[12,14]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,11]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[1,16,22]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[4,11]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[5,6,21]}],"pathway":[],"complexes":["CLN5–CLN3 endolysosomal complex"],"partners":["CLN3","TPP1","PPT1","CLN6","CLN8","SORT1","RAB7A","KCTD7"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O75503","full_name":"Bis(monoacylglycero)phosphate synthase CLN5","aliases":["Ceroid-lipofuscinosis neuronal protein 5","Protein CLN5","Palmitoyl protein thioesterase CLN5","S-depalmitoylase CLN5"],"length_aa":358,"mass_kda":41.5,"function":"Catalyzes the synthesis of bis(monoacylglycero)phosphate (BMP) via transacylation of 2 molecules of lysophosphatidylglycerol (LPG) (PubMed:37708259). BMP also known as lysobisphosphatidic acid plays a key role in the formation of intraluminal vesicles and in maintaining intracellular cholesterol homeostasis (PubMed:37708259). Can use only LPG as the exclusive lysophospholipid acyl donor for base exchange and displays BMP synthase activity towards various LPGs (LPG 14:0, LPG 16:0, LPG 18:0, LPG 18:1) with a higher preference for longer chain lengths (PubMed:37708259). Plays a role in influencing the retrograde trafficking of lysosomal sorting receptors SORT1 and IGF2R from the endosomes to the trans-Golgi network by controlling the recruitment of retromer complex to the endosomal membrane (PubMed:22431521). Regulates the localization and activation of RAB7A which is required to recruit the retromer complex to the endosomal membrane (PubMed:22431521) Exhibits palmitoyl protein thioesterase (S-depalmitoylation) activity in vitro and most likely plays a role in protein S-depalmitoylation","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/O75503/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CLN5","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CLN5","total_profiled":1310},"omim":[{"mim_id":"609055","title":"CEROID LIPOFUSCINOSIS, NEURONAL, 9; CLN9","url":"https://www.omim.org/entry/609055"},{"mim_id":"608102","title":"CLN5 INTRACELLULAR TRAFFICKING PROTEIN; CLN5","url":"https://www.omim.org/entry/608102"},{"mim_id":"607998","title":"TRIPEPTIDYL PEPTIDASE I; TPP1","url":"https://www.omim.org/entry/607998"},{"mim_id":"607042","title":"CLN3 LYSOSOMAL/ENDOSOMAL TRANSMEMBRANE PROTEIN, BATTENIN; CLN3","url":"https://www.omim.org/entry/607042"},{"mim_id":"602543","title":"BASIC TRANSCRIPTION FACTOR 3 PSEUDOGENE 11; BTF3P11","url":"https://www.omim.org/entry/602543"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CLN5"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O75503","domains":[{"cath_id":"-","chopping":"65-346","consensus_level":"medium","plddt":89.8236,"start":65,"end":346}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O75503","model_url":"https://alphafold.ebi.ac.uk/files/AF-O75503-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O75503-F1-predicted_aligned_error_v6.png","plddt_mean":82.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CLN5","jax_strain_url":"https://www.jax.org/strain/search?query=CLN5"},"sequence":{"accession":"O75503","fasta_url":"https://rest.uniprot.org/uniprotkb/O75503.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O75503/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O75503"}},"corpus_meta":[{"pmid":"19174516","id":"PMC_19174516","title":"VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19174516","citation_count":554,"is_preprint":false},{"pmid":"9662406","id":"PMC_9662406","title":"CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9662406","citation_count":225,"is_preprint":false},{"pmid":"11971870","id":"PMC_11971870","title":"Lysosomal localization of the neuronal ceroid lipofuscinosis CLN5 protein.","date":"2002","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11971870","citation_count":101,"is_preprint":false},{"pmid":"12134079","id":"PMC_12134079","title":"Neuronal ceroid lipofuscinoses are connected at molecular level: interaction of CLN5 protein with CLN2 and CLN3.","date":"2002","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/12134079","citation_count":91,"is_preprint":false},{"pmid":"16033706","id":"PMC_16033706","title":"A mutation in canine CLN5 causes neuronal ceroid lipofuscinosis in Border collie dogs.","date":"2005","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/16033706","citation_count":76,"is_preprint":false},{"pmid":"15459177","id":"PMC_15459177","title":"A mouse model for Finnish variant late infantile neuronal ceroid lipofuscinosis, CLN5, reveals neuropathology associated with early aging.","date":"2004","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15459177","citation_count":72,"is_preprint":false},{"pmid":"19941651","id":"PMC_19941651","title":"Novel interactions of CLN5 support molecular networking between Neuronal Ceroid Lipofuscinosis proteins.","date":"2009","source":"BMC cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19941651","citation_count":69,"is_preprint":false},{"pmid":"22431521","id":"PMC_22431521","title":"The role of ceroid lipofuscinosis neuronal protein 5 (CLN5) in endosomal sorting.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22431521","citation_count":68,"is_preprint":false},{"pmid":"10953198","id":"PMC_10953198","title":"Phenotype-genotype correlation in eight patients with Finnish variant late infantile NCL (CLN5).","date":"2000","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10953198","citation_count":62,"is_preprint":false},{"pmid":"17988881","id":"PMC_17988881","title":"A new large animal model of CLN5 neuronal ceroid lipofuscinosis in Borderdale sheep is caused by a nucleotide substitution at a consensus splice site (c.571+1G>A) leading to excision of exon 3.","date":"2007","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/17988881","citation_count":60,"is_preprint":false},{"pmid":"20157158","id":"PMC_20157158","title":"CLN5 mutations are frequent in juvenile and late-onset non-Finnish patients with NCL.","date":"2010","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20157158","citation_count":59,"is_preprint":false},{"pmid":"8644710","id":"PMC_8644710","title":"The age of human mutation: genealogical and linkage disequilibrium analysis of the CLN5 mutation in the Finnish population.","date":"1996","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8644710","citation_count":59,"is_preprint":false},{"pmid":"37708259","id":"PMC_37708259","title":"The Batten disease gene product CLN5 is the lysosomal bis(monoacylglycero)phosphate synthase.","date":"2023","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37708259","citation_count":58,"is_preprint":false},{"pmid":"30078766","id":"PMC_30078766","title":"Longitudinal In Vivo Monitoring of the CNS Demonstrates the Efficacy of Gene Therapy in a Sheep Model of CLN5 Batten Disease.","date":"2018","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30078766","citation_count":55,"is_preprint":false},{"pmid":"15207259","id":"PMC_15207259","title":"The mouse ortholog of the neuronal ceroid lipofuscinosis CLN5 gene encodes a soluble lysosomal glycoprotein expressed in the developing brain.","date":"2004","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/15207259","citation_count":53,"is_preprint":false},{"pmid":"28487519","id":"PMC_28487519","title":"Retinal Degeneration In A Mouse Model Of CLN5 Disease Is Associated With Compromised Autophagy.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28487519","citation_count":52,"is_preprint":false},{"pmid":"24058541","id":"PMC_24058541","title":"The role of N-glycosylation in folding, trafficking, and functionality of lysosomal protein CLN5.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24058541","citation_count":52,"is_preprint":false},{"pmid":"10477428","id":"PMC_10477428","title":"Molecular basis of the neuronal ceroid lipofuscinoses: mutations in CLN1, CLN2, CLN3, and CLN5.","date":"1999","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/10477428","citation_count":50,"is_preprint":false},{"pmid":"29128403","id":"PMC_29128403","title":"Cln5 is secreted and functions as a glycoside hydrolase in Dictyostelium.","date":"2017","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/29128403","citation_count":46,"is_preprint":false},{"pmid":"23160995","id":"PMC_23160995","title":"CLN5 and CLN8 protein association with ceramide synthase: biochemical and proteomic approaches.","date":"2012","source":"Electrophoresis","url":"https://pubmed.ncbi.nlm.nih.gov/23160995","citation_count":46,"is_preprint":false},{"pmid":"22182690","id":"PMC_22182690","title":"Cln5-deficiency in mice leads to microglial activation, defective myelination and changes in lipid metabolism.","date":"2011","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/22182690","citation_count":44,"is_preprint":false},{"pmid":"8661106","id":"PMC_8661106","title":"Efficient construction of a physical map by fiber-FISH of the CLN5 region: refined assignment and long-range contig covering the critical region on 13q22.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8661106","citation_count":44,"is_preprint":false},{"pmid":"25934231","id":"PMC_25934231","title":"Golden Retriever dogs with neuronal ceroid lipofuscinosis have a two-base-pair deletion and frameshift in CLN5.","date":"2015","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25934231","citation_count":42,"is_preprint":false},{"pmid":"15728307","id":"PMC_15728307","title":"A CLN5 mutation causing an atypical neuronal ceroid lipofuscinosis of juvenile onset.","date":"2005","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15728307","citation_count":41,"is_preprint":false},{"pmid":"19309691","id":"PMC_19309691","title":"Retention of lysosomal protein CLN5 in the endoplasmic reticulum causes neuronal ceroid lipofuscinosis in Asian sibship.","date":"2009","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/19309691","citation_count":40,"is_preprint":false},{"pmid":"30037983","id":"PMC_30037983","title":"An Alzheimer's Disease-Linked Loss-of-Function CLN5 Variant Impairs Cathepsin D Maturation, Consistent with a Retromer Trafficking Defect.","date":"2018","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30037983","citation_count":40,"is_preprint":false},{"pmid":"20052765","id":"PMC_20052765","title":"The neuronal ceroid lipofuscinosis protein CLN5: new insights into cellular maturation, transport, and consequences of mutations.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20052765","citation_count":38,"is_preprint":false},{"pmid":"19385065","id":"PMC_19385065","title":"Progressive thalamocortical neuron loss in Cln5 deficient mice: Distinct effects in Finnish variant late infantile NCL.","date":"2009","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/19385065","citation_count":38,"is_preprint":false},{"pmid":"27203721","id":"PMC_27203721","title":"Australian Cattle Dogs with Neuronal Ceroid Lipofuscinosis are Homozygous for a CLN5 Nonsense Mutation Previously Identified in Border Collies.","date":"2016","source":"Journal of veterinary internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27203721","citation_count":36,"is_preprint":false},{"pmid":"24269732","id":"PMC_24269732","title":"Inhibition of storage pathology in prenatal CLN5-deficient sheep neural cultures by lentiviral gene therapy.","date":"2013","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/24269732","citation_count":35,"is_preprint":false},{"pmid":"17607606","id":"PMC_17607606","title":"Revelation of a novel CLN5 mutation in early juvenile neuronal ceroid lipofuscinosis.","date":"2007","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/17607606","citation_count":35,"is_preprint":false},{"pmid":"30655561","id":"PMC_30655561","title":"Autophagy-lysosome pathway alterations and alpha-synuclein up-regulation in the subtype of neuronal ceroid lipofuscinosis, CLN5 disease.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30655561","citation_count":34,"is_preprint":false},{"pmid":"25359263","id":"PMC_25359263","title":"Adult-onset autosomal recessive ataxia associated with neuronal ceroid lipofuscinosis type 5 gene (CLN5) mutations.","date":"2014","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25359263","citation_count":31,"is_preprint":false},{"pmid":"32257390","id":"PMC_32257390","title":"Proteomic and functional analyses in disease models reveal CLN5 protein involvement in mitochondrial dysfunction.","date":"2020","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/32257390","citation_count":28,"is_preprint":false},{"pmid":"16814585","id":"PMC_16814585","title":"Two novel CLN5 mutations in a Portuguese patient with vLINCL: insights into molecular mechanisms of CLN5 deficiency.","date":"2006","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16814585","citation_count":28,"is_preprint":false},{"pmid":"16935476","id":"PMC_16935476","title":"Neuronal ceroid lipofuscinosis in Devon cattle is caused by a single base duplication (c.662dupG) in the bovine CLN5 gene.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16935476","citation_count":28,"is_preprint":false},{"pmid":"33930398","id":"PMC_33930398","title":"Intravitreal gene therapy protects against retinal dysfunction and degeneration in sheep with CLN5 Batten disease.","date":"2021","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/33930398","citation_count":27,"is_preprint":false},{"pmid":"28065762","id":"PMC_28065762","title":"Characterisation of early changes in ovine CLN5 and CLN6 Batten disease neural cultures for the rapid screening of therapeutics.","date":"2017","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/28065762","citation_count":27,"is_preprint":false},{"pmid":"26664787","id":"PMC_26664787","title":"Molecular neuropathology of the synapse in sheep with CLN5 Batten disease.","date":"2015","source":"Brain and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/26664787","citation_count":27,"is_preprint":false},{"pmid":"10992246","id":"PMC_10992246","title":"CLN-1 and CLN-5, genes for infantile and variant late infantile neuronal ceroid lipofuscinoses, are expressed in the embryonic human brain.","date":"2000","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10992246","citation_count":27,"is_preprint":false},{"pmid":"28468312","id":"PMC_28468312","title":"Induced Pluripotent Stem Cells Derived from a CLN5 Patient Manifest Phenotypic Characteristics of Neuronal Ceroid Lipofuscinoses.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28468312","citation_count":27,"is_preprint":false},{"pmid":"35427157","id":"PMC_35427157","title":"Cln5 represents a new type of cysteine-based S-depalmitoylase linked to neurodegeneration.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35427157","citation_count":26,"is_preprint":false},{"pmid":"30048658","id":"PMC_30048658","title":"Secretion and function of Cln5 during the early stages of Dictyostelium development.","date":"2018","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/30048658","citation_count":26,"is_preprint":false},{"pmid":"34060589","id":"PMC_34060589","title":"CLN5 and CLN3 function as a complex to regulate endolysosome function.","date":"2021","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/34060589","citation_count":26,"is_preprint":false},{"pmid":"28442266","id":"PMC_28442266","title":"CLN5 is cleaved by members of the SPP/SPPL family to produce a mature soluble protein.","date":"2017","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/28442266","citation_count":26,"is_preprint":false},{"pmid":"33792748","id":"PMC_33792748","title":"A lysosomal enigma CLN5 and its significance in understanding neuronal ceroid lipofuscinosis.","date":"2021","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/33792748","citation_count":24,"is_preprint":false},{"pmid":"27488642","id":"PMC_27488642","title":"An EEG Investigation of Sleep Homeostasis in Healthy and CLN5 Batten Disease Affected Sheep.","date":"2016","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27488642","citation_count":24,"is_preprint":false},{"pmid":"35921411","id":"PMC_35921411","title":"KCTD7 mutations impair the trafficking of lysosomal enzymes through CLN5 accumulation to cause neuronal ceroid lipofuscinoses.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35921411","citation_count":22,"is_preprint":false},{"pmid":"34680045","id":"PMC_34680045","title":"Deficiency of the Lysosomal Protein CLN5 Alters Lysosomal Function and Movement.","date":"2021","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/34680045","citation_count":21,"is_preprint":false},{"pmid":"28733362","id":"PMC_28733362","title":"Loss of Cln5 causes altered neurogenesis in a mouse model of a childhood neurodegenerative disorder.","date":"2017","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/28733362","citation_count":19,"is_preprint":false},{"pmid":"25303899","id":"PMC_25303899","title":"Neuronal ceroid lipofuscinosis genes, CLN2, CLN3 and CLN5 are spatially and temporally co-expressed in a developing mouse brain.","date":"2014","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25303899","citation_count":19,"is_preprint":false},{"pmid":"26342652","id":"PMC_26342652","title":"Proteolytic processing of the neuronal ceroid lipofuscinosis related lysosomal protein CLN5.","date":"2015","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/26342652","citation_count":18,"is_preprint":false},{"pmid":"34291044","id":"PMC_34291044","title":"Aberrant Autophagy Impacts Growth and Multicellular Development in a Dictyostelium Knockout Model of CLN5 Disease.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34291044","citation_count":17,"is_preprint":false},{"pmid":"32087303","id":"PMC_32087303","title":"Mfsd8 localizes to endocytic compartments and influences the secretion of Cln5 and cathepsin D in Dictyostelium.","date":"2020","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/32087303","citation_count":17,"is_preprint":false},{"pmid":"24038957","id":"PMC_24038957","title":"Topology and membrane anchoring of the lysosomal storage disease-related protein CLN5.","date":"2013","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/24038957","citation_count":16,"is_preprint":false},{"pmid":"11332769","id":"PMC_11332769","title":"Studies of homogenous populations: CLN5 and CLN8.","date":"2001","source":"Advances in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11332769","citation_count":15,"is_preprint":false},{"pmid":"31294445","id":"PMC_31294445","title":"Loss of Cln5 leads to altered Gad1 expression and deficits in interneuron development in mice.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31294445","citation_count":14,"is_preprint":false},{"pmid":"35681535","id":"PMC_35681535","title":"Lysosomal Proteomics Links Disturbances in Lipid Homeostasis and Sphingolipid Metabolism to CLN5 Disease.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35681535","citation_count":14,"is_preprint":false},{"pmid":"31101435","id":"PMC_31101435","title":"A mixed breed dog with neuronal ceroid lipofuscinosis is homozygous for a CLN5 nonsense mutation previously identified in Border Collies and Australian Cattle Dogs.","date":"2019","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31101435","citation_count":14,"is_preprint":false},{"pmid":"10419622","id":"PMC_10419622","title":"Prenatal diagnosis of variant late infantile neuronal ceroid lipofuscinosis (vLINCL[Finnish]; CLN5).","date":"1999","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/10419622","citation_count":13,"is_preprint":false},{"pmid":"8020979","id":"PMC_8020979","title":"A variant form of late infantile neuronal ceroid lipofuscinosis (CLN5) is not an allelic form of Batten (Spielmeyer-Vogt-Sjögren, CLN3) disease: exclusion of linkage to the CLN3 region of chromosome 16.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8020979","citation_count":11,"is_preprint":false},{"pmid":"38272448","id":"PMC_38272448","title":"Mechanisms regulating the intracellular trafficking and release of CLN5 and CTSD.","date":"2024","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/38272448","citation_count":9,"is_preprint":false},{"pmid":"36368077","id":"PMC_36368077","title":"Lysosomal dysfunction, autophagic defects, and CLN5 accumulation underlie the pathogenesis of KCTD7-mutated neuronal ceroid lipofuscinoses.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/36368077","citation_count":9,"is_preprint":false},{"pmid":"37942487","id":"PMC_37942487","title":"Efficacy of dual intracerebroventricular and intravitreal CLN5 gene therapy in sheep prompts the first clinical trial to treat CLN5 Batten disease.","date":"2023","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37942487","citation_count":9,"is_preprint":false},{"pmid":"37246363","id":"PMC_37246363","title":"Characterization of neuropathology in ovine CLN5 and CLN6 neuronal ceroid lipofuscinoses (Batten disease).","date":"2023","source":"Developmental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/37246363","citation_count":9,"is_preprint":false},{"pmid":"37614821","id":"PMC_37614821","title":"Long-term safety and dose escalation of intracerebroventricular CLN5 gene therapy in sheep supports clinical translation for CLN5 Batten disease.","date":"2023","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37614821","citation_count":9,"is_preprint":false},{"pmid":"36632184","id":"PMC_36632184","title":"Progressive MRI brain volume changes in ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinosis.","date":"2023","source":"Brain communications","url":"https://pubmed.ncbi.nlm.nih.gov/36632184","citation_count":8,"is_preprint":false},{"pmid":"32983231","id":"PMC_32983231","title":"Functional Analysis of a Novel CLN5 Mutation Identified in a Patient With Neuronal Ceroid Lipofuscinosis.","date":"2020","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32983231","citation_count":8,"is_preprint":false},{"pmid":"33507209","id":"PMC_33507209","title":"Association of the Recurrent Rare Variant c.415T>C p.Phe139Leu in CLN5 With a Recessively Inherited Macular Dystrophy.","date":"2021","source":"JAMA ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/33507209","citation_count":8,"is_preprint":false},{"pmid":"32302805","id":"PMC_32302805","title":"Novel likely disease-causing CLN5 variants identified in Pakistani patients with neuronal ceroid lipofuscinosis.","date":"2020","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32302805","citation_count":8,"is_preprint":false},{"pmid":"34141843","id":"PMC_34141843","title":"Electroretinography data from ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinoses.","date":"2021","source":"Data in brief","url":"https://pubmed.ncbi.nlm.nih.gov/34141843","citation_count":7,"is_preprint":false},{"pmid":"10191122","id":"PMC_10191122","title":"Positional cloning of the CLN5 gene defective in the Finnish variant of the LINCL.","date":"1999","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10191122","citation_count":7,"is_preprint":false},{"pmid":"30264640","id":"PMC_30264640","title":"Novel Mutations in CLN5 of Chinese Patients With Neuronal Ceroid Lipofuscinosis.","date":"2018","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30264640","citation_count":6,"is_preprint":false},{"pmid":"36347825","id":"PMC_36347825","title":"HAGLROS knockdown restrained cell proliferation, migration and invasion and facilitated apoptosis in laryngeal cancer via miR-138-5p/CLN5 axis.","date":"2022","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/36347825","citation_count":6,"is_preprint":false},{"pmid":"38055807","id":"PMC_38055807","title":"Mechanistic Insights into S-Depalmitolyse Activity of Cln5 Protein Linked to Neurodegeneration and Batten Disease: A QM/MM Study.","date":"2023","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/38055807","citation_count":6,"is_preprint":false},{"pmid":"30919163","id":"PMC_30919163","title":"The Neuronal Ceroid Lipofuscinoses-Linked Loss of Function CLN5 and CLN8 Variants Disrupt Normal Lysosomal Function.","date":"2019","source":"Neuromolecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30919163","citation_count":6,"is_preprint":false},{"pmid":"32487141","id":"PMC_32487141","title":"CLN5 in heterozygosis may protect against the development of tumors in a VHL patient.","date":"2020","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32487141","citation_count":5,"is_preprint":false},{"pmid":"33777210","id":"PMC_33777210","title":"Knockdown of CLN5 inhibits the tumorigenic properties of glioblastoma cells via the Akt/mTOR signaling pathway.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33777210","citation_count":5,"is_preprint":false},{"pmid":"40346285","id":"PMC_40346285","title":"CLN5 deficiency impairs glucose uptake and uncovers PHGDH as a potential biomarker in Batten disease.","date":"2025","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/40346285","citation_count":4,"is_preprint":false},{"pmid":"22532218","id":"PMC_22532218","title":"[Neuronal ceroid lipofuscinosis: diagnostic algorithm and clinical description of the Finnish (CLN5) and Turkish (CLN7) variants late infantile].","date":"2012","source":"Revista de neurologia","url":"https://pubmed.ncbi.nlm.nih.gov/22532218","citation_count":4,"is_preprint":false},{"pmid":"36437924","id":"PMC_36437924","title":"An altered transcriptome underlies cln5-deficiency phenotypes in Dictyostelium discoideum.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36437924","citation_count":3,"is_preprint":false},{"pmid":"10480355","id":"PMC_10480355","title":"Transcript identification on the CLN5 region on chromosome 13q22.","date":"1999","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10480355","citation_count":3,"is_preprint":false},{"pmid":"38141358","id":"PMC_38141358","title":"Characterization of two human induced pluripotent stem cell lines derived from Batten disease patient fibroblasts harbouring CLN5 mutations.","date":"2023","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/38141358","citation_count":2,"is_preprint":false},{"pmid":"41457644","id":"PMC_41457644","title":"Brain-Directed AAV Gene Therapy Rescues a Mouse Model of the CLN5 Form of Neuronal Ceroid Lipofuscinosis Disease and Normalizes a Blood Plasma Biomarker of Neurodegeneration.","date":"2026","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/41457644","citation_count":1,"is_preprint":false},{"pmid":"40181626","id":"PMC_40181626","title":"Magnetic Resonance Imaging as a Readout of CLN5 Gene Therapy Efficacy in Sheep.","date":"2025","source":"Brain and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/40181626","citation_count":1,"is_preprint":false},{"pmid":"34678132","id":"PMC_34678132","title":"A novel CLN5 mutation in Turkish patient with variant late-onset neuronal ceroid lipofuscinosis and recurrent fractures that causes severe morbidity.","date":"2021","source":"Neurocase","url":"https://pubmed.ncbi.nlm.nih.gov/34678132","citation_count":1,"is_preprint":false},{"pmid":"39667065","id":"PMC_39667065","title":"Drug-refractory epilepsy due to a novel CLN5 mutation: A report of three patients from an Indian family.","date":"2024","source":"Seizure","url":"https://pubmed.ncbi.nlm.nih.gov/39667065","citation_count":1,"is_preprint":false},{"pmid":"42031177","id":"PMC_42031177","title":"CLN5 disease-causing mutations impact lysosomal biology by affecting intracellular degradation and protein trafficking.","date":"2026","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/42031177","citation_count":0,"is_preprint":false},{"pmid":"41003830","id":"PMC_41003830","title":"Genomic insights into autosomal recessive epilepsy: novel pathogenic variants in ITPA and CLN5 identified in consanguineous families.","date":"2025","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/41003830","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.01.02.630719","title":"CLN5 deficiency impairs glucose uptake in Batten disease","date":"2025-01-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.02.630719","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.13.638174","title":"Robust analytical methods for bis(monoacylglycero)phosphate profiling in health and disease","date":"2025-02-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.13.638174","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43969,"output_tokens":6148,"usd":0.112063,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14883,"output_tokens":3911,"usd":0.086095,"stage2_stop_reason":"end_turn"},"total_usd":0.198158,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"CLN5 was identified by positional cloning as a novel gene encoding a putative transmembrane protein; three disease-causing mutations (one deletion, one nonsense, one missense) were identified in patients with Finnish variant late infantile neuronal ceroid lipofuscinosis.\",\n      \"method\": \"Positional cloning, sequence analysis of patient DNA samples\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — original positional cloning with multiple independent patient mutations confirmed in the same study, replicated across subsequent literature\",\n      \"pmids\": [\"9662406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CLN5 protein is predominantly targeted to lysosomes and is a soluble lysosomal glycoprotein (~60 kDa glycosylated, ~38-40 kDa after deglycosylation), not an integral transmembrane protein as previously predicted. The most common Finnish vLINCL mutation blocked lysosomal targeting.\",\n      \"method\": \"Confocal immunofluorescence microscopy, immunoprecipitation, deglycosylation assays (Endo H, PNGase F) in transiently transfected BHK-21 cells\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal biochemical methods in a single study, replicated in subsequent work\",\n      \"pmids\": [\"11971870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CLN5 directly interacts with CLN2 and CLN3 proteins based on co-immunoprecipitation and in vitro binding assays. Disease mutations in CLN5 abolished interaction with CLN2 but not CLN3. CLN5 is synthesized as four precursor forms from alternative initiator methionines; the longest membrane-associated form mediates interactions with CLN proteins.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding assays, Western blotting, mutagenesis\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reciprocal Co-IP plus in vitro binding with disease-mutation validation in a single rigorous study\",\n      \"pmids\": [\"12134079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CLN5 interacts with multiple NCL proteins: CLN1/PPT1, CLN2/TPP1, CLN3, CLN6, and CLN8. Over-expression of PPT1 can facilitate lysosomal transport of the mutated CLN5(FinMajor) protein normally retained in ER/Golgi. CLN5 also binds the F1-ATPase, a known PPT1-interacting partner.\",\n      \"method\": \"Co-immunoprecipitation, intracellular localization studies, co-expression assays\",\n      \"journal\": \"BMC cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP supported by functional trafficking rescue, single lab but multiple interacting partners confirmed\",\n      \"pmids\": [\"19941651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CLN5 interacts with the lysosomal sorting receptor sortilin. CLN5 depletion causes degradation of sortilin and the cation-independent mannose 6-phosphate receptor (CI-MPR) in lysosomes due to defective retromer recruitment at endosomes. CLN5 depletion also reduces active (GTP-loaded) Rab7, which is required for retromer recruitment.\",\n      \"method\": \"Co-immunoprecipitation, siRNA-mediated depletion in HeLa cells, Western blotting, fluorescence microscopy\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (Co-IP, KD with defined biochemical and trafficking phenotypes) in a single focused study\",\n      \"pmids\": [\"22431521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CLN5 has eight functional N-glycosylation sites; glycosylation at specific asparagines (N179, N252, N304, N320) is required for proper protein folding (mutants retained in ER), while glycosylation at N401 is required for lysosomal trafficking (mutant mislocalizes to Golgi). Patient mutant N192S reaches the lysosome, suggesting a functional defect at that location.\",\n      \"method\": \"Site-directed mutagenesis of N-glycosylation sites, localization studies by fluorescence microscopy in transfected cells\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic site-directed mutagenesis of all eight N-glycosylation sites with localization readout, single lab\",\n      \"pmids\": [\"24058541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CLN5 is synthesized as a type II transmembrane glycoprotein with a cytoplasmic N-terminus, one transmembrane segment, and a large luminal C-terminal domain containing an amphipathic helix (AH). The cytoplasmic and TM domains are removed by signal-peptide cleavage, and the mature CLN5 is anchored to the membrane lumen via the AH. CLN5 pathological mutants lacking the AH are retained in the ER and degraded by the proteasome.\",\n      \"method\": \"Epitope-tagged CLN5 topology mapping, membrane solubility assays, localization by fluorescence microscopy, proteasome inhibitor experiments\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic topology determination with epitope tagging plus mutagenesis of amphipathic helix and proteasomal degradation readout in a single study\",\n      \"pmids\": [\"24038957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CLN5 undergoes proteolytic cleavage at its C-terminus in an acidic compartment, requiring a cysteine protease. A ~60 kDa proprotein form is processed to a ~56 kDa mature form post-translationally. Processing can occur as early as the trans-Golgi network.\",\n      \"method\": \"Cycloheximide chase analysis, pharmacological protease inhibitors, transient transfection of patient and glycosylation mutants, Western blotting\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (chase, inhibitors, mutants), single lab\",\n      \"pmids\": [\"26342652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CLN5 is cleaved by SPPL3 (a member of the SPP/SPPL intramembrane protease family) from a type II transmembrane precursor into a mature soluble protein consisting of residues 93–407. The remaining N-terminal fragment is subsequently cleaved by SPPL3 and SPPL2b and degraded by the proteasome.\",\n      \"method\": \"Expression of tagged CLN5 constructs, overexpression/knockdown of SPPL family members, Western blotting, co-expression assays\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct identification of the specific protease (SPPL3) with functional rescue and fragment characterization, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"28442266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Both Dictyostelium Cln5 and human CLN5 function as glycoside hydrolases, as shown using fluorescent enzyme substrates. Dictyostelium Cln5 is secreted during growth and starvation and interacts with proteins involved in metabolism, catabolism, proteolysis, and hydrolysis including other NCL-like proteins (Tpp1/Cln2, cathepsin D/Cln10).\",\n      \"method\": \"Glycoside hydrolase fluorescent substrate assays, immunoprecipitation coupled with mass spectrometry, secretion assays, GFP fusion localization\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — enzyme activity demonstrated in vitro with fluorescent substrates for both Dictyostelium and human CLN5, single lab\",\n      \"pmids\": [\"29128403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"An AD-associated CLN5 variant (p.Asn320Ser) causes glycosylation defects, ER retention, and reduced delivery to the endolysosomal compartment. This variant reduces normal processing of cathepsin D and decreases levels of full-length amyloid precursor protein (APP), consistent with a defect in retromer-dependent trafficking.\",\n      \"method\": \"Expression of variant CLN5 in cells, Western blotting for glycosylation, immunofluorescence for localization, cathepsin D maturation assay, APP level measurement\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal assays (glycosylation, localization, downstream substrate processing) in a single focused study\",\n      \"pmids\": [\"30037983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CLN5 and CLN3 function as an endolysosomal complex. CLN5 deletion results in impaired endolysosome fusion events, delayed degradation of endocytic proteins, and defective autophagy. CLN5 modulates these pathways by regulating downstream interactions between CLN3, RAB7A, and a subset of RAB7A effectors.\",\n      \"method\": \"CLN5 knockout/knockdown in HeLa cells, Co-immunoprecipitation for CLN3-RAB7A-effector interactions, endolysosome fusion assays, autophagy flux assays\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cellular assays plus Co-IP identifying the CLN3–RAB7A–effector regulatory axis, single lab\",\n      \"pmids\": [\"34060589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CLN5 (Cln5) has cysteine palmitoyl thioesterase (S-depalmitoylation) activity. The crystal structure revealed homology to the catalytic domain of the N1pC/P60 superfamily of papain-like enzymes, and mutational analysis showed that the predicted catalytic residues histidine-166 and cysteine-280 are critical for thioesterase activity. CLN5-deficient neuronal progenitor cells show reduced thioesterase activity.\",\n      \"method\": \"Crystal structure determination, site-directed mutagenesis (H166A, C280A), fluorescent substrate (DDP-5) thioesterase assay, CLN5-deficient cell line thioesterase activity measurement\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus mutagenesis of catalytic residues plus in vitro enzyme activity plus loss-of-function cellular validation; multiple orthogonal methods in one study\",\n      \"pmids\": [\"35427157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The CRL3-KCTD7 ubiquitin ligase complex targets CLN5 for ubiquitination and proteasomal degradation. NCL patient-derived KCTD7 mutations disrupt KCTD7–CUL3 or KCTD7–CLN5 interactions, causing excessive CLN5 accumulation. Accumulated CLN5 disrupts the interaction between CLN6/CLN8 and lysosomal enzymes at the ER, impairing ER-to-Golgi trafficking of lysosomal enzymes.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, KCTD7 knockout/patient-mutation cell lines, Western blotting for lysosomal enzyme trafficking\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical reconstitution of ubiquitination, reciprocal Co-IP, disease-mutation functional rescue, and downstream pathway phenotype all in one study\",\n      \"pmids\": [\"35921411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CLN5 is the lysosomal BMP synthase (BMPS). CLN5-deficient cells exhibit massive accumulation of the BMP precursor lysophosphatidylglycerol (LPG), depletion of BMP species, and dysfunctional lipid metabolism. Mechanistically, CLN5 mediates BMP synthesis through an energy-independent base exchange reaction between two LPG molecules, with increased activity on BMP-laden vesicles.\",\n      \"method\": \"BMPS-deficient cell generation, lipidomic profiling (LPG and BMP quantitation), in vitro enzymatic assay reconstitution with LPG substrates, BMP-laden vesicle activity assay\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted enzymatic activity in vitro with substrate identification and mechanistic (base exchange) characterization, plus orthogonal cellular lipidomics validation\",\n      \"pmids\": [\"37708259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"QM/MM computational analysis of the CLN5 crystal structure confirmed that S-depalmitoylation proceeds via a catalytic triad Cys280–His166–Glu183, and that S-depalmitoylation (barrier ~26.1 kcal/mol) is the rate-limiting step compared to the preceding S-palmitoylation step (~25.3 kcal/mol).\",\n      \"method\": \"QM/MM calculations at ωB97X-D/6-31G(d,p):AMBER level, NBO charge analysis, local mode stretching force constants\",\n      \"journal\": \"Journal of the American Chemical Society\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — rigorous computational mechanistic study grounded in the experimental crystal structure, but purely computational (no new experimental validation in this paper)\",\n      \"pmids\": [\"38055807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CLN5 undergoes proteolytic cleavage to generate a mature polypeptide transported to lysosomes. CLN5 can also traffic to lysosomes via a mannose-6-phosphate receptor-independent pathway. All analyzed disease-causing mutations disrupt lysosomal trafficking of CLN5 proteins, but the degree of lysosomal mistargeting does not correlate with disease onset.\",\n      \"method\": \"Transient and stable expression in HeLa cells, pulse-chase metabolic labeling, immunofluorescence localization, M6P receptor blocking experiments\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple expression systems and biochemical methods demonstrating M6P-independent trafficking, single lab\",\n      \"pmids\": [\"20052765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In cells lacking CLN5, lysosomal movement/trafficking is impaired in human cortical-like glutamatergic neurons, and lysosomal enzyme activity and acidic organelle content are reduced.\",\n      \"method\": \"CRISPRi knockdown of CLN5 in iPSC-derived human neurons, live-cell imaging of lysosomal movement, microscopy and flow cytometry for acidic organelles, lysosomal enzyme activity assay\",\n      \"journal\": \"Biomolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPRi in human neurons with direct lysosomal movement imaging and functional enzyme assays, single lab\",\n      \"pmids\": [\"34680045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CLN5 loss leads to mitochondrial dysfunction and impaired mitophagy. A mitochondria-focused proteomics approach in CLN5 KO cells and Cln5-/- mouse cerebral cortex revealed impairment of mitochondrial respiratory function and activation of mitophagy pathways, correlated with disease progression.\",\n      \"method\": \"Quantitative mitochondria-focused proteomics (label-free), mitochondrial respiration assays, immunofluorescence for mitophagy markers, validation in patient fibroblasts\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — orthogonal proteomics plus functional respiration assays in multiple disease models including patient cells, single lab\",\n      \"pmids\": [\"32257390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CLN5 deficiency causes elevated basal LC3-II levels and increased autophagic flux in patient fibroblasts and CLN5-knockdown HeLa cells. Alpha-synuclein (α-syn) gene SNCA is highly upregulated at mRNA and protein levels in CLN5-deficient cells, and α-syn localizes near lysosomes. Knockdown of SNCA reversed lysosomal perinuclear clustering caused by CLN5 deficiency.\",\n      \"method\": \"Western blotting (LC3-II), tandem fluorescent mRFP-GFP-LC3 autophagy flux assay, qPCR for SNCA, immunofluorescence for α-syn localization, SNCA siRNA rescue experiment\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods with genetic rescue experiment (siRNA), single lab\",\n      \"pmids\": [\"30655561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In Dictyostelium, Cln5 is released from cells via signal-peptide-mediated secretion and through pathways linked to autophagy. Release requires autophagy proteins Atg1, Atg5, and Atg9, as well as autophagosomal-lysosomal fusion. Release also requires microfilaments and Dictyostelium homologs of AP-3, LYST, mucopilin-1, and WASH (regulators of lysosomal exocytosis). Cln5 release is regulated by the amount of extracellular CtsD (cathepsin D).\",\n      \"method\": \"Genetic knockouts of autophagy genes, cytoskeleton inhibitor experiments, secretion assays with Western blotting and mass spectrometry in Dictyostelium\",\n      \"journal\": \"Traffic (Copenhagen, Denmark)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic genetic dissection with multiple knockout lines, single lab/model organism\",\n      \"pmids\": [\"38272448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In wild-type CLN5 mutant cells (CLN5 p.Trp379Cys and p.Leu358AlafsX4), both mutant CLN5 proteins are retained in the endoplasmic reticulum rather than reaching the lysosome, as demonstrated by double immunofluorescence microscopy. The truncation mutant lacks an N-glycosylation site at Asn401.\",\n      \"method\": \"Double immunofluorescence microscopy, expression analysis, Western blotting in patient-derived cell lines\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization in patient-derived mutant cells, confirms Asn401 glycosylation requirement for lysosomal targeting, single study\",\n      \"pmids\": [\"19309691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Mouse Cln5 is a soluble lysosomal glycoprotein. In situ hybridization and immunohistochemistry showed prominent expression in cerebellar Purkinje cells, cerebral neurons, hippocampal pyramidal cells, and interneurons, with expression beginning at E15 and increasing through development.\",\n      \"method\": \"In situ hybridization, immunohistochemistry, in vitro expression in COS-1, HeLa, and neuronal cells\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization and expression studies confirming soluble lysosomal nature in multiple cell types, single lab\",\n      \"pmids\": [\"15207259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CLN5-deficient fibroblasts show decreased levels of ceramide, sphingomyelin, and glycosphingolipids, and reduced ceramide synthase activity. CLN8 protein expression can correct growth and apoptosis defects in CLN5-deficient cells. Comparison by Co-IP and differential gel electrophoresis revealed absence of γ-actin in the CerS1-bound protein complex in CLN5-deficient cells.\",\n      \"method\": \"Co-immunoprecipitation, differential gel electrophoresis, mass spectrometry, ceramide species measurement by MS, cell viability and apoptosis assays\",\n      \"journal\": \"Electrophoresis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical and proteomic methods in patient-derived cells, single lab\",\n      \"pmids\": [\"23160995\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CLN5 encodes a soluble lysosomal glycoprotein that is translated as a type II transmembrane precursor, processed by SPPL3 intramembrane protease cleavage into a mature soluble form anchored by an amphipathic helix; it has at least two enzymatic activities—a BMP (bis(monoacylglycero)phosphate) synthase activity that catalyzes BMP biosynthesis via base exchange between two lysophosphatidylglycerol molecules, and a cysteine palmitoyl thioesterase (S-depalmitoylation) activity requiring catalytic residues His166 and Cys280; it regulates retromer recruitment to endosomes (in part by maintaining active Rab7 levels) to control lysosomal sorting receptor recycling, functions as part of an endolysosomal complex with CLN3 to regulate RAB7A effector interactions and endolysosome fusion, interacts with multiple other NCL proteins (CLN1/PPT1, CLN2/TPP1, CLN3, CLN6, CLN8), and is itself subject to ubiquitin-mediated degradation by the CRL3-KCTD7 E3 ligase complex.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CLN5 encodes a soluble lysosomal glycoprotein whose loss causes Finnish variant late infantile neuronal ceroid lipofuscinosis, a phenotype traced to multiple disease-causing mutations identified at its original positional cloning [#0]. Although originally predicted to be a transmembrane protein, CLN5 is synthesized as a type II transmembrane precursor that is converted to a mature soluble lysosomal glycoprotein anchored to the luminal membrane leaflet by an amphipathic helix, with the cytoplasmic and transmembrane segments removed by SPPL3-mediated intramembrane proteolysis to yield mature residues 93–407 [#1, #6, #8]. N-glycosylation governs both folding and trafficking, with distinct glycosylation sites required for ER exit versus lysosomal delivery, and CLN5 can reach lysosomes by a mannose-6-phosphate-receptor-independent route [#5, #16]; pathogenic mutants are mistargeted and retained in the ER for proteasomal degradation [#6, #21]. CLN5 carries two enzymatic activities: it is the lysosomal BMP synthase that builds bis(monoacylglycero)phosphate by an energy-independent base-exchange reaction between two lysophosphatidylglycerol molecules [#14], and it is a cysteine palmitoyl thioesterase whose papain-like N1pC/P60 fold uses a Cys280–His166–Glu183 catalytic triad to mediate S-depalmitoylation [#12, #15]. Functionally, CLN5 controls endolysosomal sorting and fusion: it binds the sorting receptors sortilin and CI-MPR and sustains active Rab7 to support retromer recruitment at endosomes [#4], and it acts with CLN3 to regulate RAB7A-effector interactions and endolysosome fusion, autophagy, and degradative flux [#11]. CLN5 physically interacts with the broader NCL protein network (CLN1/PPT1, CLN2/TPP1, CLN3, CLN6, CLN8) [#2, #3], and its abundance is set by CRL3-KCTD7-mediated ubiquitination and proteasomal degradation, with KCTD7 disease mutations causing pathological CLN5 accumulation that disrupts CLN6/CLN8-dependent lysosomal enzyme trafficking [#13]. Consistent with these roles, CLN5 deficiency produces lipid imbalance, impaired lysosomal motility and acidification in neurons, mitochondrial dysfunction, and dysregulated autophagy [#14, #17, #18, #19].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established CLN5 as a disease gene by linking its mutation to a defined neurodegenerative lysosomal storage disorder, providing the entry point for all mechanistic work.\",\n      \"evidence\": \"Positional cloning and patient DNA sequencing in Finnish variant late infantile neuronal ceroid lipofuscinosis\",\n      \"pmids\": [\"9662406\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The original cloning predicted a transmembrane topology that was later overturned\", \"No molecular function assigned at identification\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Resolved the basic nature and protein interactions of CLN5, showing it is a soluble lysosomal glycoprotein rather than an integral membrane protein and that it engages other NCL proteins.\",\n      \"evidence\": \"Confocal microscopy, deglycosylation, immunoprecipitation in BHK-21 cells, and reciprocal Co-IP/in vitro binding with disease-mutation validation\",\n      \"pmids\": [\"11971870\", \"12134079\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the protease producing the soluble form\", \"Functional consequence of CLN2/CLN3 binding unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Expanded the NCL interaction network and showed cross-rescue of trafficking, establishing CLN5 as a hub among ceroid lipofuscinosis proteins.\",\n      \"evidence\": \"Co-IP, localization, and co-expression rescue assays plus patient-mutant ER retention in patient-derived cells\",\n      \"pmids\": [\"19941651\", \"19309691\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interactions largely single-lab Co-IP without reconstitution\", \"Stoichiometry and directness of multi-NCL binding unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined a trafficking-regulatory function: CLN5 supports retromer-dependent recycling of lysosomal sorting receptors by maintaining active Rab7.\",\n      \"evidence\": \"Co-IP with sortilin, siRNA depletion in HeLa cells with receptor degradation and Rab7-GTP readouts\",\n      \"pmids\": [\"22431521\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which CLN5 sustains Rab7-GTP not defined\", \"Whether enzymatic activity underlies the trafficking effect not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Reconciled topology with maturation by showing CLN5 is a type II transmembrane precursor anchored after cleavage by an amphipathic helix, with N-glycosylation partitioned between folding and trafficking roles.\",\n      \"evidence\": \"Topology mapping with epitope tags, membrane solubility assays, systematic N-glycosylation site mutagenesis, proteasome inhibition\",\n      \"pmids\": [\"24038957\", \"24058541\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the cleaving protease still unknown at this stage\", \"Functional output of mature CLN5 not yet defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified SPPL3 as the intramembrane protease generating mature soluble CLN5, closing the maturation pathway.\",\n      \"evidence\": \"Tagged CLN5 constructs with SPPL family overexpression/knockdown and fragment characterization by Western blot\",\n      \"pmids\": [\"28442266\", \"29128403\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Glycoside hydrolase activity reported but substrate identity unresolved\", \"Relationship between SPPL3 processing and downstream function unaddressed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placed CLN5 in an endolysosomal complex with CLN3 that regulates RAB7A-effector interactions, linking it directly to endolysosome fusion and autophagy.\",\n      \"evidence\": \"CLN5 knockout/knockdown in HeLa cells, Co-IP of CLN3-RAB7A-effector axis, fusion and autophagy flux assays\",\n      \"pmids\": [\"34060589\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical architecture of the CLN5-CLN3 complex not solved\", \"Single-lab functional dataset\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Assigned a defined catalytic activity—cysteine palmitoyl thioesterase—via crystal structure and catalytic-residue mutagenesis, and showed CLN5 abundance is controlled by CRL3-KCTD7 ubiquitination.\",\n      \"evidence\": \"Crystal structure, H166A/C280A mutagenesis, fluorescent thioesterase assay, and ubiquitination assays with KCTD7 patient-mutation cell lines\",\n      \"pmids\": [\"35427157\", \"35921411\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological palmitoylated substrates of CLN5 thioesterase activity not identified\", \"How thioesterase activity relates to trafficking phenotypes unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established CLN5 as the lysosomal BMP synthase and detailed the chemical mechanism of its second activity, giving the protein two distinct enzymatic functions.\",\n      \"evidence\": \"BMPS-deficient cells with lipidomics, in vitro reconstitution of LPG base-exchange, and QM/MM mechanistic analysis of S-depalmitoylation\",\n      \"pmids\": [\"37708259\", \"38055807\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BMP synthase and thioesterase activities use the same active site is not established\", \"Which activity drives the disease phenotype unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Characterized the cellular consequences of CLN5 loss across organelles, connecting the gene to lipid imbalance, neuronal lysosomal dysfunction, mitochondrial defects, and altered autophagy.\",\n      \"evidence\": \"iPSC-neuron CRISPRi imaging, mitochondrial proteomics in KO cells and Cln5-/- mouse cortex, autophagy flux and SNCA rescue, and Dictyostelium secretion genetics\",\n      \"pmids\": [\"34680045\", \"32257390\", \"30655561\", \"38272448\", \"23160995\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal ordering between primary enzymatic loss and downstream organelle phenotypes unclear\", \"Many phenotypes are single-lab or model-organism observations\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how CLN5's two enzymatic activities (BMP synthase and depalmitoylase) and its trafficking-regulatory role are mechanistically integrated, and which is the primary driver of neurodegeneration.\",\n      \"evidence\": \"No timeline study unifies the enzymatic and trafficking functions into a single causal model\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No defined physiological thioesterase substrate\", \"No structural model linking active site to BMP synthesis\", \"Disease-relevant primary defect unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [14]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [12, 15]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [12, 14]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [1, 16, 22]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [4, 11]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [5, 6, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005770\", \"supporting_discovery_ids\": []}\n    ],\n    \"complexes\": [\n      \"CLN5–CLN3 endolysosomal complex\"\n    ],\n    \"partners\": [\n      \"CLN3\",\n      \"TPP1\",\n      \"PPT1\",\n      \"CLN6\",\n      \"CLN8\",\n      \"SORT1\",\n      \"RAB7A\",\n      \"KCTD7\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}